In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NHSX Brings A New Digital Dimension In UK

New Digital Opportunities Must Be Shaped By Healthtech

Executive Summary

The UK continues to build its digital health care infrastructure, as seen in the recent funding pledge for a new AI Lab. Andrew Davies is the newly appointed digital health lead at the UK’s ABHI medtech industry association. He says stakeholders first need to understand the scope of digital health care, and then adopt a networked approach, with medtech playing a full part in that evolution.

You may also be interested in...



All About Value – Brexit Aside, UK Industry Sees Good Things Ahead For Healthtech Adoption

ABHI director of value and access Luella Trickett talks about the importance of real-world evidence in product development and value-based procurement in secondary care in the UK.

AI Tops The Tech Priorities For UK NHS With New Govt Funding Pledge

With health care in the UK being increasingly restructured around digital delivery, bodies like the new NHSX, NHS Digital and the forthcoming Digital Innovation Hubs will be in the forefront of health-care policy-making at the national level. A new government funding pledge has underlined the importance of taking the opportunities that artificial intelligence, machine learning and genomic medicine offer in health care.

MedTech Forum 2019: Consumers And Wellness, Or Patients And Health Care?

As health care transitions to digitally enabled wellness, medtechs will be missing a trick if they persist in holding onto the delivery, business methods and models that were the standard of the early 2000s. Heightened expectations of the new options for dealing with personal health mean that new opportunities are there for the taking – but industry shouldn’t let the tech companies have it all their own way, advised ZS principal Brian Chapman.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV124319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel